Table 4.

Synergy of gentamicin and SEQ-914 against MRSA-295 biofilms in CAMHB

Treatment group	Concn (μg/ml)a	Log10 no. of CFU/biofilm (mean ± SD)b	Log reduction
Pretreatmentc		8.24 ± 0.29
Untreated control		9.34 ± 0.07
GEN	2	9.03 ± 0.07	−0.79
	4	7.99 ± 0.08	0.25
	8	6.11 ± 0.21	2.14
	16	3.87 ± 0.64	4.37
SEQ-914	16	8.57 ± 0.06	−0.33
	32	5.86 ± 0.53	2.39
GEN–SEQ-914	0.5; 8d	5.79 ± 1.01	2.45
	1; 4	7.50 ± 0.17	0.75
	1; 8	4.44 ± 0.69	3.81
	2; 2	7.15 ± 0.48	1.10
	2; 4	6.70 ± 0.28	1.55
	2; 8	3.59 ± 0.42	4.66

^aBiofilm assay concentration.

^bA minimum of two independent experiments were performed, with three wells per experiment. Data are reported as averages (n = 6 as a minimum) for these experiments.

^cThis is the biofilm at 5 h prior to treatment.

^dGEN and SEQ-914 concentrations, respectively.